Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.

Rucaparib boosts PFS in BRCA-mutant recurrent ovarian cancer

Elaine Tan
21 Sep 2017

Rucaparib maintenance therapy increases progression-free survival (PFS) in BRCA-mutant recurrent ovarian cancer (OC) by 77 percent, according to late-breaking results from the ARIEL3 trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain.

The trial investigated PFS in 564 patients with high-grade recurrent OC (disease progression ≥6 months after penultimate platinum) who had achieved either a complete response (according to RECIST v1.1) or partial response (RECIST v1.1 or Gynecologic Cancer InterGroup CA-125 criteria) to their last platinum-based therapy. The patients were randomized in a 2:1 ratio to receive rucaparib 600 mg BID maintenance therapy or placebo. [ESMO 2017, abstract LBA40_PR]

Investigators assessed the PFS benefit of rucaparib (a PARP inhibitor with antitumour activity in BRCA-mutant OC or BRCA wild-type OC with high genomic loss of heterozygosity [LOH]) vs placebo sequentially in three groups: group 1 comprising patients with BRCA mutations (deleterious germline or somatic BRCA mutation), group 2 comprising patients with homologous recombination deficient (HRD) OC (BRCA-mutant or BRCA wild-type with high LOH), and group 3 comprising the entire intent-to-treat population.

“Results showed that compared with placebo, rucaparib led to a significant improvement in median PFS in all three groups, with the greatest improvement seen in group 1 [5.4 vs 16.6, 13.6 and 10.8 months, respectively; p<0.0001; hazard ratios, 0.23, 0.32, and 0.36, respectively],” reported lead author Professor Jonathan Ledermann of UCL Cancer Institute, London, UK.

Exploratory analyses in non-nested subgroups of patients with BRCA wild-type OC found that rucaparib treatment significantly improved PFS vs placebo. “However, as expected, a greater magnitude of PFS benefit was seen in those with high LOH [median PFS, 11.1 vs 5.6 months with placebo; p=0.0135] than those with low LOH [median PFS, 8.2 vs 5.3 months; p=0.0003],” said Ledermann.

“PFS benefit with rucaparib treatment was not dependent on time to progression since penultimate platinum therapy or whether patients had partial or complete response to their last platinum therapy,” he highlighted.

In ARIEL3, rucaparib was well tolerated with a safety profile consistent with previous phase II studies. The most common grade 3 treatment-emergent adverse events (TEAEs) associated with rucaparib were anaemia (18.8 percent vs 0.5 percent with placebo) and increase in alanine/aspartate aminotransferase levels (10.5 vs 0 percent).  “However, elevations were transient, self-limiting and not associated with other signs of liver toxicity,” Ledermann noted.

At the visit cut-off date (15 Apr 2017), 13.4 percent of patients in the rucaparib group vs 1.6 percent in the placebo group discontinued treatment due to TEAEs (excluding disease progression), and 1.6 vs 1.1 percent died due to adverse events (including disease progression).

“PARP inhibitors are the biggest development in OC therapy since the introduction of platinum drugs in the late 1970s and early 1980s. Rucaparib is clearly an exemplary member of this exciting class of drugs that can be used to treat women with recurrent OC in the maintenance setting,” Ledermann concluded.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.